Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Collegium Pharmaceutical (COLL)

Collegium Pharmaceutical chairman and director to retire; Gino Santini named next chair

Neutral Impact 3 of 5 leadership Written later

Collegium Pharmaceutical said founder and Chairman Michael Heffernan and director Gwen Melincoff will not stand for re-election at the 2025 Annual Meeting. The board named lead independent director Gino Santini as Chairman effective after that meeting, and the company said the departures are part of board refreshment and succession planning, not a disagreement. The filing also announced David Dieter as Executive Vice President and General Counsel, effective March 17, 2025.

Key points

  • Michael Heffernan, founder and Chairman, advised the board on March 11, 2025 that he will retire at the Annual Meeting; he has served on the board since October 2003
  • Gwen Melincoff, a director since 2017, will also retire at the Annual Meeting
  • Gino Santini, lead independent director since 2018, becomes Chairman effective immediately after the Annual Meeting
  • Dr. Carlos Paya was nominated on March 14, 2025 to stand for election at the Annual Meeting; David Dieter became General Counsel on March 17, 2025

The filing

CompanyCollegium Pharmaceutical (COLL)
Form8-K, current report
Filed with the SECMar 17, 2025, 7:05 AM ET
Accession number0001104659-25-024185

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:07 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 17, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.